Charles Schwab Investment Management Inc. Has $14.74 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Charles Schwab Investment Management Inc. increased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 4.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 381,494 shares of the specialty pharmaceutical company’s stock after purchasing an additional 16,655 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.18% of Collegium Pharmaceutical worth $14,741,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in COLL. Gladius Capital Management LP acquired a new stake in Collegium Pharmaceutical in the 2nd quarter valued at $32,000. nVerses Capital LLC lifted its stake in shares of Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares during the last quarter. CWM LLC grew its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the last quarter. Finally, AXA S.A. bought a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $209,000.

Analyst Upgrades and Downgrades

Several analysts have recently commented on COLL shares. Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright increased their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The trade was a 15.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.98% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $29.97 on Friday. The firm has a market cap of $966.53 million, a price-to-earnings ratio of 12.92 and a beta of 0.80. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a 50-day simple moving average of $34.20 and a two-hundred day simple moving average of $34.51. Collegium Pharmaceutical, Inc. has a 12-month low of $26.09 and a 12-month high of $42.29.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.